Shopping Cart
- Remove All
- Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $74 | In Stock | |
2 mg | $107 | In Stock | |
5 mg | $166 | In Stock | |
10 mg | $288 | In Stock | |
25 mg | $571 | In Stock | |
50 mg | $819 | In Stock | |
100 mg | $1,130 | In Stock | |
1 mL x 10 mM (in DMSO) | $223 | In Stock |
Description | Mizagliflozin is an orally active, selective SGLT1 inhibitor with a Ki value of 27 nM for human SGLT1. Mizagliflozin is 303 times more selective for SGLT1 than for SGLT2. Mizagliflozin is an anti-diabetic drug that can improve postprandial blood sugar fluctuations and may have the potential to improve chronic constipation. |
Targets&IC50 | SGLT1 (human):(ki)27 nM, SGLT2 (human):8170 nM(ki) |
In vivo | METHODS: Mizagliflozin (GSK-1614235 free base) (0.3 mg/kg, intravenous administration) and oral administration (3 mg/kg, oral administration) were administered to rats to study its pharmacokinetics and metabolite profile. RESULTS Mizagliflozin had different half-lives in rats (0.23 and 1.14 hours, respectively) depending on the administration route; the absolute bioavailability was only 0.02%; after oral administration, Mizagliflozin was mainly metabolized to its aglycone KP232 in the intestine. [2] |
Alias | KGA-3235 free base, GSK-1614235 free base, DSP-3235 free base |
Molecular Weight | 564.67 |
Formula | C28H44N4O8 |
Cas No. | 666843-10-3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | Methanol: 250 mg/mL (442.74 mM), Sonication is recommended. DMSO: 100 mg/mL (177.09 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO/Methanol
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.